Overview

NAC for Treating Comorbid PTSD and SUD

Status:
Completed
Trial end date:
2019-11-04
Target enrollment:
Participant gender:
Summary
As a result of sustained operations in Afghanistan and Iraq, there are an increasing number of U.S. military Veterans with substance use disorders and comorbid posttraumatic stress disorder (PTSD). If left untreated, individuals with substance use disorders and PTSD are at increased risk for developing other mental health problems (e.g., depression, anxiety), suicidal ideation and attempts, medical problems, reduced resiliency and military readiness, vocational problems, and family/social impairment. This study will determine the benefits of N-acetylcysteine (NAC) in treating alcohol use disorder and comorbid post-traumatic stress disorder (PTSD) among military Veterans.
Phase:
Phase 2
Details
Lead Sponsor:
Medical University of South Carolina
Collaborators:
Institute for Translational Neuroscience
United States Department of Defense
Treatments:
Acetylcysteine
N-monoacetylcystine